Up­dat­ed: Two years on from con­fir­ma­to­ry tri­al halt, FDA sub­mits more ques­tions to On­copep­tides over Pepax­to with­draw­al

Fol­low­ing up on last week’s meet­ing on FDA’s long-await­ed pro­pos­al to with­draw the ac­cel­er­at­ed ap­proval for On­copep­tides’ blood can­cer drug Pepax­to (mel­pha­lan flufe­namide), the FDA has more ques­tions on the com­pa­ny’s con­fir­ma­to­ry tri­al.

It’s been more than two years since the Swedish-based On­copep­tides first pre­sent­ed to the FDA the dis­cour­ag­ing re­sults of the tri­al, known as OCEAN, fol­low­ing its 2021 ac­cel­er­at­ed ap­proval of Pepax­to as a fifth-line ther­a­py for mul­ti­ple myelo­ma.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER